Different genetic and epigenetic mechanisms can deregulate the RHO GTPase signaling network in lymphomas and, in general, in human tumors; the variability of alterations found in different tumors reflects the complex regulation of this signaling in normal cells. This evidence concerns the gene RHO and lymphoma.